✦ LIBER ✦

PCN37 Cost Comparison of Erlotinib Versus Generic Docetaxel in Second-Line Non-Small Cell Lung Cancer in Italy

✍ Scribed by Schwander, B.; Ravera, S.; Giuliani, G.; Nuijten, M.; Walzer, S.

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

PCN90 Cost-Effectiveness Analysis of Erl

✍ Nguyen, T.T.T.; Yagudina, R.; Kulikov, A. 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 58 KB

PCN25 COST-EFFECTIVENESS ANALYSIS OF ERL

✍ Kim, YG; Lee, EK 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 65 KB

PCN9 ERLOTINIB IN NON-SMALL CELL LUNG CA

✍ A Gabriel; O Pirk; W Kotowa 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 72 KB

PCN37 Cost-Minimization Analysis of Seco

✍ Laurendeau, C.; Chouaid, C.; Florentin, V.; Duchon D'engenières, V.; Detournay, 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 62 KB

Docetaxel in Second-Line Treatment of no

✍ Frank V. Fossella 📂 Article 📅 2002 🏛 CIG Media Group, LP. 🌐 English ⚖ 142 KB

PCN6: MODELLING THE COST-EFFECTIVENESS O

✍ P Sharplin; UK Bose; J Holmes 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 52 KB